HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
J Cui, T Xia, D Xie, Y Gao, Z Jia, D Wei, L Wang… - Oncogene, 2016 - nature.com
Hepatocyte growth factor (HGF)/Met signaling has critical roles in pancreatic ductal
adenocarcinoma (PDA) development and progression and is considered a potential …
adenocarcinoma (PDA) development and progression and is considered a potential …
The Hepatocyte Growth Factor (HGF)/met axis: a neglected target in the treatment of chronic myeloproliferative neoplasms?
M Boissinot, M Vilaine, S Hermouet - Cancers, 2014 - mdpi.com
Met is the receptor of hepatocyte growth factor (HGF), a cytoprotective cytokine. Disturbing
the equilibrium between Met and its ligand may lead to inappropriate cell survival …
the equilibrium between Met and its ligand may lead to inappropriate cell survival …
HIF-1α is a crucial factor in the development of peritoneal dissemination via natural metastatic routes in scirrhous gastric cancer
S Miyake, Y Kitajima, J Nakamura… - International …, 2013 - spandidos-publications.com
The molecular mechanisms underlying the peritoneal dissemination of gastric cancer
remain unclear. Using in vivo metastatic models, this study attempted to clarify the role of …
remain unclear. Using in vivo metastatic models, this study attempted to clarify the role of …
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets
FM Franco, DE Jones, PKW Harris, Z Han… - Bioorganic & Medicinal …, 2015 - Elsevier
Hepatocyte growth factor activator (HGFA), matriptase and hepsin are all S1 trypsin-like
serine endopeptidases. HGFA is a plasma protease while hepsin and matriptase are type II …
serine endopeptidases. HGFA is a plasma protease while hepsin and matriptase are type II …
c-Met pathway in human malignancies and its targeting by natural compounds for cancer therapy
CD Mohan, MK Shanmugam, SGS Gowda… - Phytomedicine, 2024 - Elsevier
Background c-MET is a receptor tyrosine kinase which is classically activated by HGF to
activate its downstream signaling cascades such as MAPK, PI3K/Akt/mTOR, and STAT3 …
activate its downstream signaling cascades such as MAPK, PI3K/Akt/mTOR, and STAT3 …
Signaling pathways in pancreatic cancer
M Korc, M Preis - Critical Reviews™ in Eukaryotic Gene …, 2011 - dl.begellhouse.com
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy characterized by a
plethora of molecular alterations that include major and minor driving mutations, the …
plethora of molecular alterations that include major and minor driving mutations, the …
Hepatocyte growth factor from a clinical perspective: A pancreatic cancer challenge
W Rizwani, AE Allen, JG Trevino - Cancers, 2015 - mdpi.com
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States
and incidence rates are rising. Both detection and treatment options for pancreatic cancer …
and incidence rates are rising. Both detection and treatment options for pancreatic cancer …
MET and VEGF: synergistic targets in castration-resistant prostate cancer
DT Aftab, DM McDonald - Clinical and Translational Oncology, 2011 - Springer
Recent advances in the treatment of prostate cancer have resulted in improved outcomes,
including longer survival, but new options are needed for treating patients with castration …
including longer survival, but new options are needed for treating patients with castration …
Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal‑regulated kinase signaling …
T Vanichapol, K Leelawat… - Molecular medicine …, 2015 - spandidos-publications.com
Hypoxia is associated with tumor progression and poor prognosis in several cancer types.
The present study aimed to examine the contribution of hypoxia (1% O2) to cancer …
The present study aimed to examine the contribution of hypoxia (1% O2) to cancer …
Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer
M Preusser, B Streubel, AS Berghoff… - …, 2014 - Wiley Online Library
Background CMET represents an emerging therapy target for monoclonal antibodies and
tyrosine kinase inhibitors in non‐small cell lung cancer (NSCLC). Methods We investigated …
tyrosine kinase inhibitors in non‐small cell lung cancer (NSCLC). Methods We investigated …